Tanespimycin (17-AAG)

Catalog No.S1141 Synonyms: CP127374,NSC-330507, KOS 953

Tanespimycin (17-AAG) Chemical Structure

Molecular Weight(MW): 585.69

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Size Price Stock Quantity  
In DMSO USD 195 In stock
USD 150 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

9 Customer Reviews

  • (A) Cell lines were seeded in 96-well plates and treated with 10 nM of 17-AAG for 72 h. Cell survival was analyzed using CellTiter-Glo. Both parental H3122 cells (red bar) and H3122 CR cells (blue bar) show sensitivity to 17-AAG. (B) Suppression of ALK signaling by 17-AAG in resistant H3122 CR cells. H3122 parental and resistant cells were exposed to increasing concentrations of 17-AAG for 6 h.

    PNAS, 2011, 108: 7535-40. Tanespimycin (17-AAG) purchased from Selleck.

    (A) Treatment of DIPG cells with an HSP90 inhibitor, 17-AAG, resulted in decreased invasion toward SVZ hNPC CM at high doses. (B) Cell viability of DIPG cells treated with increasing doses of 17-AAG, by the CellTiter-Glo assay.

    Cell, 2017, 170(5):845-859.e19. Tanespimycin (17-AAG) purchased from Selleck.

  • Four types of the colon cancer cells with indicated K-Ras phenotype were incubated with indicated concentration of 17-AAG for 24 h, which were then analyzed for protein expression by WB.

    Oncotarget 2014 5, 4269-82. Tanespimycin (17-AAG) purchased from Selleck.

    Western blot analysis of immunoprecipitated Hsp90/BIP complexes in MOLT-4 (T-ALL) and RS4;11 (B-ALL) treated for 22 h with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. 500 μg of protein lysates were immunoprecipitated with anti-Hsp90 antibody. Relative Induction values (Rel.Ind.) were obtained by normalizing to Hsp90 bands density. 17-AAG: tanespimycin.

    Oncotarget, 2015, 51: S659-S660. Tanespimycin (17-AAG) purchased from Selleck.

  • Co-IP analyses of direct interaction between HSP90 and HIF-1α in 17-AAG (5 μM)-treated HSCs using antibodies against HSP90, HIF-1α or IgG (n = 2).

    Br J Pharmacol, 2017, 174(5):409-423. Tanespimycin (17-AAG) purchased from Selleck.

    UPR modulators destabilize mSmoM2. NIH 3T3 cells expressing mSmoM2 protein were treated with HSP90 inhibitors 17-AAG (50 uM and 100 uM) and SNX-2112 (25 uM and 50 uM) and the proteasome inhibitor bortezomib (25 uM and 50 uM) for 4 h prior to lysis. DMSO was the vehicle control. Western blotting of whole-cell lysates revealed mSmoM2 protein to be destabilized in response to HSP-90 inhibitors but not in response to bortezomib. Tubulin was the loading control. CHOP results indicate ER stress.

    Mol Cell Biol 2013 33(12), 2375-87. Tanespimycin (17-AAG) purchased from Selleck.

  • Treatment with an Hsp90 inhibitor results in a dose-dependent decrease in complex IV activity. A, because Hsp90 levels were reduced by 80%, in PINK1 null dopaminergic neuronal cells, the effects of specific inhibition of Hsp90 using 17-AAG were analyzed in wild-type neuronal cells. Both complex IV activity and Hsp60 levels were decreased significantly in 17-AAG-treated cells in a dose-dependent manner. B, in contrast, 17-AAG treatment did not affect expression of Hsp90 and LRPPRC.

    J Biol Chem 2012 287, 44109-20. Tanespimycin (17-AAG) purchased from Selleck.

    SKBR3 cells were treated with FW-04-806 at 10, 20, 40 uM for 24 h; 17AAG was used as a positive control at 1 and 2 uM. Hsp70, Hsp90, and Cdc37 protein level were analyzed with western blotting using relevant antibodies.

    Mol Cancer 2014 13, 150. Tanespimycin (17-AAG) purchased from Selleck.

  • Hsp90 is up-regulated during aging. Whole-cell extracts were prepared from young (PD 20) and old (PD 40) HFSN1 cells. c HFSN1 cells (PD 40) were treated with different concentration of the Hsp90 inhibitor (17-AAG) and then re-incubated for 24 h. Whole-cell extracts were prepared and analyzed by western blot using the indicated antibodies.

    Age 2013 35, 549-62. Tanespimycin (17-AAG) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.
Features Displays very low toxicity toward normal cells.
Targets
HSP90 [1]
(Cell-free assay)
5 nM
In vitro

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. [1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. [2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 M1\MU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTvTWM2OD1yLkCwNFMxOyEQvF2= Mlm1V2FPT0WU
IST-MEL1 M1Lxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrINld[UUN3ME2wMlAxODRyNzFOwG0> NWK4fZNsW0GQR1XS
NCI-SNU-1 NYfQTVl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LWOGlEPTB;MD6wNFIxPyEQvF2= M2HnTnNCVkeHUh?=
FADU MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwMECyNFkh|ryP NHnvdo5USU6JRWK=
C32 MnP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnOTFEyUUN3ME2wMlAxOzB2IN88US=> M2XpR3NCVkeHUh?=
D-566MG MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M175UGlEPTB;MD6wNFM6KM7:TR?= NFu5eWtUSU6JRWK=
LXF-289 MkKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LXbmlEPTB;MD6wNFQyQSEQvF2= MYrTRW5ITVJ?
HGC-27 NVjwW5VxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwMEC1NUDPxE1? NUezUHVzW0GQR1XS
RPMI-7951 NHPvb3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NET2cXVKSzVyPUCuNFA4OTdizszN NYfr[IhvW0GQR1XS
HSC-3 M{H0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn2xTWM2OD1yLkCwPVI6KM7:TR?= NFrqSIdUSU6JRWK=
MIA-PaCa-2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDUSZFKSzVyPUCuNFExODlizszN M2fBT3NCVkeHUh?=
KS-1 M1LlVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXtXIZKSzVyPUCuNFE{PTVizszN NVTLdpo4W0GQR1XS
CAL-51 MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTBwMEG0NFUh|ryP NVq4Wok2W0GQR1XS
MDA-MB-361 NU\KfZB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIP2TY1KSzVyPUCuNFE1QTVizszN NVPtT2Q2W0GQR1XS
TI-73 NFvGdXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwMEG3PVYh|ryP NELxT5dUSU6JRWK=
AGS MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2i2SWlEPTB;MD6wNVk{QCEQvF2= MlXvV2FPT0WU
NCI-H460 NVnYOJduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3HUW02UUN3ME2wMlAyQTd2IN88US=> MVPTRW5ITVJ?
A204 NV3OXYljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HuZmlEPTB;MD6wNlI1QSEQvF2= NITp[pNUSU6JRWK=
CHL-1 M{PndGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PVWWlEPTB;MD6wNlI2OSEQvF2= Mki1V2FPT0WU
DU-4475 NWS0b5RwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfXcnFQUUN3ME2wMlAzOjZzIN88US=> NFzUdZBUSU6JRWK=
CGTH-W-1 NECwNXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[yUoNMUUN3ME2wMlAzOzR7IN88US=> NWjsPGIxW0GQR1XS
HCC2218 NWLwVWRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMEK0PVQh|ryP M1nGZ3NCVkeHUh?=
A2780 NIfCXIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfFTWM2OD1yLkCyOVMyKM7:TR?= NWjRRlB5W0GQR1XS
NCI-H720 M3TjUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwMEK1OFYh|ryP MX3TRW5ITVJ?
NCI-N87 NYfMbIZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4riXWlEPTB;MD6wNlU6OyEQvF2= NHzSdopUSU6JRWK=
CHP-212 NUTEenJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYewT2l[UUN3ME2wMlAzPjJ6IN88US=> Mlz4V2FPT0WU
NCI-H23 MmLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jaT2lEPTB;MD6wNlY3PSEQvF2= Ml3XV2FPT0WU
D-263MG NV\zZ4F5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMEK3PFYh|ryP MXTTRW5ITVJ?
ME-180 MkjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TlN2lEPTB;MD6wNlg6OSEQvF2= M1;JbnNCVkeHUh?=
SW982 NWn0O3RWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlG0TWM2OD1yLkCyPVk6KM7:TR?= MUTTRW5ITVJ?
OE19 M2rEVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4OxOmlEPTB;MD6wN|A4PyEQvF2= M1XSWXNCVkeHUh?=
SK-LU-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfXSWttUUN3ME2wMlA{ODh{IN88US=> Mom0V2FPT0WU
H4 MnT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXZTWM2OD1yLkCzNFkh|ryP M3PZO3NCVkeHUh?=
HT-144 NWHjUW06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX64SVBwUUN3ME2wMlA{ODl|IN88US=> NVfFVpRXW0GQR1XS
SK-UT-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnr5TWM2OD1yLkCzNVc5KM7:TR?= MX3TRW5ITVJ?
D-336MG MkKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTnU|FGUUN3ME2wMlA{OzB7IN88US=> Mn;UV2FPT0WU
MDA-MB-175-VII MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHoTWM2OD1yLkCzN|U1KM7:TR?= NGC5bVZUSU6JRWK=
GAMG MnPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;0TWM2OD1yLkCzOFM2KM7:TR?= NH\yWohUSU6JRWK=
CP50-MEL-B MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwMEO0OUDPxE1? M3jhZXNCVkeHUh?=
OVCAR-5 NWfVZ5p6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrQSo5KSzVyPUCuNFM1QCEQvF2= M1ThXnNCVkeHUh?=
SK-MES-1 NYjDVVJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwMEO2NFYh|ryP MmDZV2FPT0WU
VM-CUB-1 MkLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PKUmlEPTB;MD6wN|Y2PyEQvF2= MnTaV2FPT0WU
WM-115 NXPxc2FYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPPelRKSzVyPUCuNFM4PjJizszN NFv3XGlUSU6JRWK=
DSH1 MoXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEH4T25KSzVyPUCuNFM5ODdizszN NHuyVIFUSU6JRWK=
Becker MkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDGTWM2OD1yLkCzPFg2KM7:TR?= NUX5SVhLW0GQR1XS
SW962 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjLV49FUUN3ME2wMlA{QTR3IN88US=> NGnXcGZUSU6JRWK=
TYK-nu MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYS2fZBWUUN3ME2wMlA{QTh3IN88US=> MmDTV2FPT0WU
HO-1-N-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2OxXGlEPTB;MD6wOFAzOSEQvF2= NHjHNVhUSU6JRWK=
T98G M4LKbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwMESxNFMh|ryP MkPwV2FPT0WU
ACN MkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwMESxOlIh|ryP MYDTRW5ITVJ?
SW780 NHzFNmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPiTWM2OD1yLkC0NlA{KM7:TR?= NX[0PGI{W0GQR1XS
Detroit562 NH:wNpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTw[3NJUUN3ME2wMlA1OjN7IN88US=> MVjTRW5ITVJ?
BB49-HNC MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGK4PWpKSzVyPUCuNFQzPDNizszN NFX4W3dUSU6JRWK=
HN NUPtO5JLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XIeGlEPTB;MD6wOFI4OiEQvF2= NF\MfGNUSU6JRWK=
H9 NWHIUolST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwMESzO|Eh|ryP MWrTRW5ITVJ?
VA-ES-BJ NGnS[XRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTBwMES0OFch|ryP NVTlcpdSW0GQR1XS
MEL-JUSO M1\odWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\1RWlEPTB;MD6wOFQ4PSEQvF2= NHTNUFdUSU6JRWK=
BT-474 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULPb3ZLUUN3ME2wMlA1PSEQvF2= NWHaUpBHW0GQR1XS
CaR-1 NVLydlZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXQXVRKSzVyPUCuNFQ2PDlizszN NFu4SYRUSU6JRWK=
PSN1 MlTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHybnpjUUN3ME2wMlA1PjB|IN88US=> NF7ON3pUSU6JRWK=
KYSE-510 NXn6fmMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\xeFJOUUN3ME2wMlA1PjR7IN88US=> NYnmUJNHW0GQR1XS
KP-4 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\vdWlEPTB;MD6wOFc2OyEQvF2= Mn;UV2FPT0WU
KYSE-410 NWLVO2xET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwMES3O|Ih|ryP MkPiV2FPT0WU
G-402 NGTDd|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\EemRLUUN3ME2wMlA1Pzh7IN88US=> MUfTRW5ITVJ?
DOK NFHTPYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwMES5NFIh|ryP Mkj4V2FPT0WU
COR-L88 NEXUWIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\P[2hKSzVyPUCuNFQ6OTJizszN NGrlXYJUSU6JRWK=
SKG-IIIa MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfaVndKSzVyPUCuNFQ6QDZizszN NETFSW1USU6JRWK=
AN3-CA NX\keVBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF23bpdKSzVyPUCuNFUh|ryP NV\tbZNCW0GQR1XS
SW48 NYHRbYFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkD5TWM2OD1yLkC1NFM6KM7:TR?= M{LRUHNCVkeHUh?=
YKG-1 NHzZPZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHu4XJBKSzVyPUCuNFUxPzFizszN MWTTRW5ITVJ?
KYSE-150 Mmn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{W0cWlEPTB;MD6wOVI{PSEQvF2= M2i0RXNCVkeHUh?=
HuO-3N1 NWnSeWFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLXXGRKSzVyPUCuNFUzOzdizszN MV3TRW5ITVJ?
LB1047-RCC Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPWNnBKSzVyPUCuNFUzQTZizszN NWrqbVVJW0GQR1XS
NCI-H2030 NVnrVYJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPBTWM2OD1yLkC1OFE1KM7:TR?= MYnTRW5ITVJ?
YH-13 Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHUTWM2OD1yLkC1O|IzKM7:TR?= MY\TRW5ITVJ?
5637 M1;xPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PLcGlEPTB;MD6wOVc1KM7:TR?= MmfqV2FPT0WU
LOXIMVI MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37ue2lEPTB;MD6wOVg4OiEQvF2= NX;LNnZzW0GQR1XS
GT3TKB Ml\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4ezXGlEPTB;MD6wOVk1OiEQvF2= MmexV2FPT0WU
TCCSUP NF74OHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwMEW5OlQh|ryP M{PJSXNCVkeHUh?=
EPLC-272H NFrXZYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXWPItKSzVyPUCuNFYzODVizszN NV7NOnZvW0GQR1XS
LU-99A NYPHPXl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwME[yN|ch|ryP MUHTRW5ITVJ?
NCI-H1755 NW\jSoZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2n5dGlEPTB;MD6wOlM1OSEQvF2= Ml;UV2FPT0WU
KM12 Mk\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWm2XotRUUN3ME2wMlA3OzR6IN88US=> NXXoTYM2W0GQR1XS
SF295 NH6wdYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2SxTmlEPTB;MD6wOlQ2OiEQvF2= Moj4V2FPT0WU
MZ2-MEL MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkm3TWM2OD1yLkC2OVU{KM7:TR?= NFqwZoRUSU6JRWK=
HEC-1 M2XoTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3ZOJRtUUN3ME2wMlA3PTh6IN88US=> MmfPV2FPT0WU
SW684 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7xfo9NUUN3ME2wMlA3PTlzIN88US=> M4[xVXNCVkeHUh?=
SF539 NX75U3JGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwME[2PFEh|ryP NGDHUnhUSU6JRWK=
GMS-10 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHKTWM2OD1yLkC2Olk6KM7:TR?= MYnTRW5ITVJ?
MV-4-11 NYnGWFhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjpTVhKSzVyPUCuNFY5ODNizszN MnfWV2FPT0WU
HT-29 NWT0U21qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwME[5NVkh|ryP NX7wT3VPW0GQR1XS
23132-87 NGe4NWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwME[5OUDPxE1? NHnJNGJUSU6JRWK=
SW620 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3ETWM2OD1yLkC3NFI3KM7:TR?= NHPPc|JUSU6JRWK=
HCC1806 NWrLNmpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDPfIhwUUN3ME2wMlA4OTNzIN88US=> M4K0XHNCVkeHUh?=
Hs-578-T NEHMRohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLV[lVKSzVyPUCuNFczODhizszN M4fleXNCVkeHUh?=
A2058 M1r2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwMEeyNlgh|ryP MYnTRW5ITVJ?
MEL-HO NFPEZ4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzVWYtKSzVyPUCuNFczPTVizszN NWHkfFZPW0GQR1XS
HCC2998 MkXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTrTWM2OD1yLkC3N|Q4KM7:TR?= MnywV2FPT0WU
HuO9 M2HXRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmD6TWM2OD1yLkC3OVg6KM7:TR?= MYLTRW5ITVJ?
CAL-39 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwMEe3OlYh|ryP M4jmS3NCVkeHUh?=
M14 MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzoNVdKUUN3ME2wMlA4QTF|IN88US=> Mn:yV2FPT0WU
BFTC-909 NVHTOWtjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7LNGYxUUN3ME2wMlA4QTZ7IN88US=> M1XRRXNCVkeHUh?=
TE-11 NV7KcYNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVWyTY1RUUN3ME2wMlA4QTl4IN88US=> NIHPPHJUSU6JRWK=
TGBC1TKB NVzBS4k1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjWfYtEUUN3ME2wMlA5ODR|IN88US=> M2nZOHNCVkeHUh?=
L-363 NHK2OZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwMEiyNFYh|ryP NUe5b5JPW0GQR1XS
A431 NHziWlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPiTWM2OD1yLkC4NlEh|ryP MnO1V2FPT0WU
MKN45 NXu2b2NDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HnUmlEPTB;MD6wPFIyQSEQvF2= MV7TRW5ITVJ?
HT-1080 M{nnWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXNTWM2OD1yLkC4OFM6KM7:TR?= M{fyW3NCVkeHUh?=
OVCAR-8 NUDXVWpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzYTWM2OD1yLkC4OlIzKM7:TR?= NIfsNZFUSU6JRWK=
LCLC-97TM1 NWnJfWY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jJeGlEPTB;MD6wPFczQCEQvF2= M2Gzd3NCVkeHUh?=
M059J MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTGTWM2OD1yLkC5NFI4KM7:TR?= MX7TRW5ITVJ?
SK-MEL-2 NFTJXplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwMEmwOkDPxE1? M3fHR3NCVkeHUh?=
TE-1 MnnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn72TWM2OD1yLkC5NlA1KM7:TR?= M2T0bXNCVkeHUh?=
KYSE-180 NXrNT4txT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\nbFJKSzVyPUCuNFkzPjJizszN NHT0U3ZUSU6JRWK=
D-247MG M1jxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjjeZI{UUN3ME2wMlA6PDV3IN88US=> Mk\QV2FPT0WU
8-MG-BA NH\1cmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHqb3pJUUN3ME2wMlA6PDd{IN88US=> NVKzSoh[W0GQR1XS
NCI-H1792 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTue5hKSzVyPUCuNFk3OThizszN NUTyV5l4W0GQR1XS
MCF7 Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XFe2lEPTB;MD6wPVY4PyEQvF2= M37EOXNCVkeHUh?=
NCI-H2122 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwMEm3OFUh|ryP NXfJdoc5W0GQR1XS
EFO-27 NGfrNG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Pmc2lEPTB;MD6wPVk6PyEQvF2= M{\VWHNCVkeHUh?=
LB2241-RCC Mk\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULjS3BZUUN3ME2wMlExODV2IN88US=> NUDmb5JPW0GQR1XS
SN12C NUfkXYtNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTkelFEUUN3ME2wMlExOTB5IN88US=> NF;IN3VUSU6JRWK=
A498 MkLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHzSo9[UUN3ME2wMlExOThizszN NH3IbI5USU6JRWK=
PANC-03-27 M3zoVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXP6dFlNUUN3ME2wMlExOjh4IN88US=> NWjNVYV2W0GQR1XS
NCI-H1581 NX;nNGh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvvTplKSzVyPUCuNVAzQSEQvF2= NWmxfmV2W0GQR1XS
U-87-MG NEHQXGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XrT2lEPTB;MD6xNFMxPyEQvF2= M33DO3NCVkeHUh?=
G-401 NILXV5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnxRo5KSzVyPUCuNVA{PTNizszN MX7TRW5ITVJ?
SiHa M3f5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLMZXBYUUN3ME2wMlExPDh4IN88US=> M2\UVXNCVkeHUh?=
U251 NXLWSnh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXHXW15UUN3ME2wMlExPTJ3IN88US=> NF7tNWFUSU6JRWK=
MMAC-SF NEjrSYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjH[ZpKSzVyPUCuNVA2OzFizszN MV3TRW5ITVJ?
BB65-RCC MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfGOnpKSzVyPUCuNVA2PTRizszN MnLuV2FPT0WU
NKM-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3VdmVKSzVyPUCuNVA3PjZizszN Mm[zV2FPT0WU
HD-MY-Z M{P5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwMUC4O|Mh|ryP NYfNd2ZiW0GQR1XS
TGBC11TKB MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4raUWlEPTB;MD6xNFkxOyEQvF2= NF62dVNUSU6JRWK=
COLO-679 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{CyN2lEPTB;MD6xNVIyOSEQvF2= NWjiUWU4W0GQR1XS
TE-8 NEjsclJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LpfmlEPTB;MD6xNVI3PCEQvF2= NGXFVm1USU6JRWK=
SK-MEL-28 M{XtRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7Fcpd[UUN3ME2wMlEyOzJzIN88US=> NVO3ZXhYW0GQR1XS
SH-4 MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XkRWlEPTB;MD6xNVM2PiEQvF2= M1jlV3NCVkeHUh?=
KALS-1 NWfHW2s6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;nSGlEPTB;MD6xNVM6OyEQvF2= M3KzbnNCVkeHUh?=
RKO NUP1Om9qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2SzcWlEPTB;MD6xNVc3PCEQvF2= NGf6NIhUSU6JRWK=
OMC-1 NGLUWoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nLPGlEPTB;MD6xNVc6PyEQvF2= MknUV2FPT0WU
BT-549 MmrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHhe5ZKSzVyPUCuNVE4QTlizszN MWDTRW5ITVJ?
NCI-H28 NU\JNllDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwMUG4NVch|ryP M365[3NCVkeHUh?=
RXF393 MljYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTBwMUG5PFIh|ryP NYfMNHd5W0GQR1XS
COLO-829 NVvkVpd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfMOXJKSzVyPUCuNVIxODVizszN MYDTRW5ITVJ?
HMV-II MmXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzvTWM2OD1yLkGyNFIh|ryP MWLTRW5ITVJ?
SW1990 NEXwOoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDiWmhKSzVyPUCuNVIyPTdizszN MkCyV2FPT0WU
NCI-H1437 MkO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTPTWM2OD1yLkGyNVU4KM7:TR?= MYnTRW5ITVJ?
SNB75 M{H2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXiTWM2OD1yLkGyNVY6KM7:TR?= NXvvNWdoW0GQR1XS
EW-3 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfOXIRKSzVyPUCuNVI3PjFizszN MnLOV2FPT0WU
SAS Mmm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHiTWM2OD1yLkGyOlkh|ryP NUPSO3l5W0GQR1XS
NCI-H1666 MorhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTBwMUK3O|Qh|ryP NYDlVm4xW0GQR1XS
A375 NX3YeWNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDBTotSUUN3ME2wMlEzPzd6IN88US=> NV7GeHZ3W0GQR1XS
CAMA-1 M1\uNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPDTWM2OD1yLkGyPVI1KM7:TR?= M2jaW3NCVkeHUh?=
HuP-T4 M4rvWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYmxU2xbUUN3ME2wMlEzQTR|IN88US=> NIfiTYhUSU6JRWK=
NCI-H292 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zsbmlEPTB;MD6xN|EyKM7:TR?= NUfvbYo6W0GQR1XS
PC-14 NXjDOZBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDEc4JVUUN3ME2wMlE{OjFzIN88US=> NILtV2lUSU6JRWK=
BPH-1 NY\jR|ltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIS1TVRKSzVyPUCuNVM1OSEQvF2= NUTYU3V{W0GQR1XS
GAK MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\nPGlEPTB;MD6xN|U3PyEQvF2= M3HYc3NCVkeHUh?=
VMRC-RCZ NVPwb4p4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEL0cmRKSzVyPUCuNVM4PjJizszN MX\TRW5ITVJ?
SK-MEL-24 NIq4cFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPJdmJKSzVyPUCuNVM5PyEQvF2= MYTTRW5ITVJ?
LB831-BLC MoXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnvTWM2OD1yLkGzPFg{KM7:TR?= MYDTRW5ITVJ?
NCI-H2452 NXnrRnhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvtVVFnUUN3ME2wMlE{QTV4IN88US=> NXHrVYl[W0GQR1XS
RT-112 NFGyOIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHmVlJKSzVyPUCuNVQxOzVizszN NWi2dZZyW0GQR1XS
GP5d MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LwNmlEPTB;MD6xOFExPCEQvF2= MmLXV2FPT0WU
LC-2-ad MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\BfolbUUN3ME2wMlE1OTJzIN88US=> M3vpUnNCVkeHUh?=
MPP-89 M1vONWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPMXnpDUUN3ME2wMlE1OTJ3IN88US=> M{O2VXNCVkeHUh?=
NUGC-3 Ml3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoThTWM2OD1yLkG0OFc5KM7:TR?= M{HueHNCVkeHUh?=
GI-1 M3SwNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PkbWlEPTB;MD6xOFU2QCEQvF2= NFG1TYlUSU6JRWK=
HCC1419 NELTU3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzwTWM2OD1yLkG0OVc3KM7:TR?= Moj3V2FPT0WU
SW1573 NHr5VINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTzU5VmUUN3ME2wMlE1PzV6IN88US=> NWO5c5c1W0GQR1XS
NCI-H2347 NV\ldG1iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLmTWM2OD1yLkG0PFM6KM7:TR?= NUfQcZpVW0GQR1XS
Mewo MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3v5OmlEPTB;MD6xOFg5QSEQvF2= NWDIZ3pLW0GQR1XS
639-V NYrBZW1YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\uNmlEPTB;MD6xOVAyOyEQvF2= MUTTRW5ITVJ?
AsPC-1 MonBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPSdGpKSzVyPUCuNVUzOjVizszN M4TBNHNCVkeHUh?=
NCI-H1648 Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrqZlFKSzVyPUCuNVUzOzJizszN NEnJT5NUSU6JRWK=
786-0 M{TmWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXCclFuUUN3ME2wMlE2OzhzIN88US=> Mmq1V2FPT0WU
ETK-1 Mme3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HoU2lEPTB;MD6xOVkh|ryP MWHTRW5ITVJ?
BxPC-3 MoDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDHNmVrUUN3ME2wMlE2QTZ4IN88US=> NWDsOXhEW0GQR1XS
CAL-62 MmCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHmcolKSzVyPUCuNVYyPjlizszN MX3TRW5ITVJ?
HCC1937 M3XZOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\ETWM2OD1yLkG2Nlc2KM7:TR?= MYjTRW5ITVJ?
NCI-H1299 M3jNOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzDSHV2UUN3ME2wMlE3Ojh3IN88US=> MVzTRW5ITVJ?
SW1088 M2L4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2e4cmlEPTB;MD6xOlQyOyEQvF2= MoLGV2FPT0WU
FTC-133 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIL6OnBKSzVyPUCuNVY2PCEQvF2= MV\TRW5ITVJ?
OC-314 Mkn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfHR2huUUN3ME2wMlE3PjlizszN MUXTRW5ITVJ?
SCC-9 MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwMU[3NVYh|ryP NWLCfJFOW0GQR1XS
HT-1376 NUfvN5A{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfxTWM2OD1yLkG2PVM3KM7:TR?= NVvOUZBXW0GQR1XS
U-2-OS NGO2V2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXiTWM2OD1yLkG3NVc{KM7:TR?= NF\DWHpUSU6JRWK=
COLO-824 MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTBwMUeyPVQh|ryP MX\TRW5ITVJ?
BB30-HNC MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFe3PVZKSzVyPUCuNVc{OyEQvF2= NUC2UnV[W0GQR1XS
NCI-H2087 NXfDRnZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUf0ZoFxUUN3ME2wMlE4OzZ6IN88US=> MlPEV2FPT0WU
NCI-H2170 NULmTIR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTBwMUe1N|Yh|ryP NGLhfmlUSU6JRWK=
SK-OV-3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvJTWM2OD1yLkG3OVcyKM7:TR?= M2rSPHNCVkeHUh?=
MZ7-mel MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwMUe2OFkh|ryP NVjBbVR2W0GQR1XS
NCI-H650 NHvN[mxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwMUe2PFIh|ryP NGm0NoxUSU6JRWK=
KOSC-2 NWL2fFI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFi1bplKSzVyPUCuNVc4OzRizszN NFzHXHNUSU6JRWK=
SCC-4 NYPvU3o{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXITWM2OD1yLkG3O|c4KM7:TR?= MX3TRW5ITVJ?
MDA-MB-157 MlzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFv1bJZKSzVyPUCuNVgxQDJizszN M4K0VnNCVkeHUh?=
KYSE-520 NYDlWpB6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITDcWlKSzVyPUCuNVgzKM7:TR?= M{jabXNCVkeHUh?=
LK-2 Mnr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHFTWM2OD1yLkG4N|A{KM7:TR?= NF2yUnFUSU6JRWK=
KNS-81-FD MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknlTWM2OD1yLkG4N|k1KM7:TR?= MkfGV2FPT0WU
IGROV-1 M1fzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moe1TWM2OD1yLkG4OFQ{KM7:TR?= MorMV2FPT0WU
DEL NV\Jcmo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TQfGlEPTB;MD6xPFQ2KM7:TR?= NYTFcHhLW0GQR1XS
NCI-H1395 MmrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknpTWM2OD1yLkG4OlgzKM7:TR?= MUPTRW5ITVJ?
JEG-3 NGnOS4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXztXnpJUUN3ME2wMlE5PzB3IN88US=> M3zWR3NCVkeHUh?=
BCPAP NWSxSGdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorGTWM2OD1yLkG4PFczKM7:TR?= NILXNIlUSU6JRWK=
CAL-27 NHy1PIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVq1TVZuUUN3ME2wMlE6ODJ{IN88US=> NUHWdFVIW0GQR1XS
RD M1zWVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfleZRKSzVyPUCuNVkyOTNizszN NG\HR|JUSU6JRWK=
RVH-421 NHW2VlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmL2TWM2OD1yLkG5NVE3KM7:TR?= NIHPOJBUSU6JRWK=
Capan-2 MmTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2WzVmlEPTB;MD6xPVI2PiEQvF2= NIHvZXJUSU6JRWK=
COLO-680N NVO1OVFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzzSG5KSzVyPUCuNVk{PjRizszN MknsV2FPT0WU
NCI-H1650 MnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPvXJNKSzVyPUCuNlAxPTdizszN MW\TRW5ITVJ?
SBC-5 MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwMkCxNVgh|ryP MoH3V2FPT0WU
U031 NVvFRXVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXDTWM2OD1yLkKwOVQ4KM7:TR?= M1\OXXNCVkeHUh?=
S-117 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTBwMkC1OlQh|ryP MkLEV2FPT0WU
DoTc2-4510 NY[wSXdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHKR4ZKSzVyPUCuNlA4PjlizszN MnjwV2FPT0WU
AM-38 M{T0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFGwOpVKSzVyPUCuNlA5PDhizszN M2my[3NCVkeHUh?=
A172 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHwTWM2OD1yLkKxNFIzKM7:TR?= MVfTRW5ITVJ?
HPAF-II NYO5RVdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vwOGlEPTB;MD6yNVI3PCEQvF2= M1\qV3NCVkeHUh?=
769-P MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13Q[mlEPTB;MD6yNVI5KM7:TR?= MWnTRW5ITVJ?
MFE-280 NEfjOJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnoXHFTUUN3ME2wMlIyOjl6IN88US=> NHHrRXlUSU6JRWK=
TE-9 NXXwO3lCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHW5eJFKSzVyPUCuNlE4QDZizszN NUHPSYZCW0GQR1XS
C2BBe1 Mny2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwMkKxPUDPxE1? NV;idZRsW0GQR1XS
EoL-1-cell NX\NTXI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwMkKyNFMh|ryP NF;Ze29USU6JRWK=
G-361 M2LqSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorsTWM2OD1yLkKyOlgzKM7:TR?= M2fmOnNCVkeHUh?=
KYSE-270 M3jpXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrLfHZKSzVyPUCuNlMxQDRizszN MoPIV2FPT0WU
TK10 MoDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTBwMkOxNVch|ryP MoD3V2FPT0WU
ML-2 M1nyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwMkOxNVkh|ryP MXLTRW5ITVJ?
MHH-ES-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwMkO2PFEh|ryP MlvDV2FPT0WU
BHY MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnBTWM2OD1yLkKzOlkyKM7:TR?= NYLwRW45W0GQR1XS
LS-513 NGfBU4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDYdoVKSzVyPUCuNlM6PjFizszN MX3TRW5ITVJ?
COLO-678 MlPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHXN41TUUN3ME2wMlI1ODR2IN88US=> NHTiSVZUSU6JRWK=
NCI-H747 MkHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;EW29KSzVyPUCuNlQyPjlizszN NFjFc41USU6JRWK=
K5 NF\p[YVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFyyW5JKSzVyPUCuNlQ{QCEQvF2= NUSwcYk4W0GQR1XS
OS-RC-2 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHPU4lKSzVyPUCuNlQ2ODlizszN NELvVXJUSU6JRWK=
KINGS-1 M17JXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPDSJFKSzVyPUCuNlQ2OjlizszN M2\EXHNCVkeHUh?=
SCC-25 M3XQNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwMkS1OlMh|ryP MlXPV2FPT0WU
CAPAN-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVruVlBYUUN3ME2wMlI1Pzh|IN88US=> NHmyNFJUSU6JRWK=
ESS-1 NVXsdFV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXK0Nm16UUN3ME2wMlI1QDB3IN88US=> NWn1e5lVW0GQR1XS
TE-6 NWP0OWNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLwTWM2OD1yLkK1O|Uh|ryP NETObXhUSU6JRWK=
LB2518-MEL NETuXnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwMkW3O|ch|ryP NHvVTlhUSU6JRWK=
COLO-800 M{eyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnK2TWM2OD1yLkK1PFEzKM7:TR?= MVrTRW5ITVJ?
LU-134-A MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDzTWM2OD1yLkK2NVM3KM7:TR?= MknvV2FPT0WU
NCI-H1155 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwMk[xOlIh|ryP NV[4coV5W0GQR1XS
MFM-223 M2rhe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vxUWlEPTB;MD6yOlM3OyEQvF2= M4rO[HNCVkeHUh?=
HTC-C3 NWG5bW9OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwMk[1NFYh|ryP MV\TRW5ITVJ?
HCT-116 M13qZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnTSJRKSzVyPUCuNlY2QTlizszN NHPG[IdUSU6JRWK=
Ca-Ski M1nrXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nRXGlEPTB;MD6yOlY4QCEQvF2= MUnTRW5ITVJ?
SBC-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwMk[3OFIh|ryP NHr6SIxUSU6JRWK=
NB69 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwMkewPFch|ryP MVrTRW5ITVJ?
J82 M3rmSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwMkeyOlUh|ryP MnrlV2FPT0WU
U-118-MG NEHlWphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDR[|VKSzVyPUCuNlc2PzlizszN NX\vcpdbW0GQR1XS
NCI-H1355 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jOfWlEPTB;MD6yPFA4PCEQvF2= NUDUfHRXW0GQR1XS
NCI-H1048 M1ntXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTBwMki5OVYh|ryP MmDVV2FPT0WU
SW954 M1\pWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYS4VYtGUUN3ME2wMlI6OjJ5IN88US=> NXS1bok5W0GQR1XS
NMC-G1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTBwMkmyO|ch|ryP MoPUV2FPT0WU
SW1710 Mm\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwMkm0PVQh|ryP MVnTRW5ITVJ?
KY821 MlnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFy3WVNKSzVyPUCuNlk5PzJizszN M4P5bXNCVkeHUh?=
HCC38 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzJTWM2OD1yLkOwNFc5KM7:TR?= NVHnWY83W0GQR1XS
NCI-SNU-5 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfpTWM2OD1yLkOwOVQh|ryP M3;JSnNCVkeHUh?=
ES8 Ml61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHnZ5BKSzVyPUCuN|A4QDRizszN MYjTRW5ITVJ?
COLO-792 M1TtbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LPTGlEPTB;MD6zNVI2OSEQvF2= MUnTRW5ITVJ?
BFTC-905 MnP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLqTWM2OD1yLkOxOVIyKM7:TR?= MUDTRW5ITVJ?
ChaGo-K-1 NVnrRmtIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTBwM{G3NVUh|ryP MWfTRW5ITVJ?
Daoy MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTUfZE3UUN3ME2wMlMyPzJ|IN88US=> MWHTRW5ITVJ?
SJSA-1 NYfRSo9JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jSeWlEPTB;MD6zNVg1PyEQvF2= NYDtWGV{W0GQR1XS
KNS-62 NUj4W|YyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfkTWM2OD1yLkOyNFg5KM7:TR?= NGL5No9USU6JRWK=
CAKI-1 MlX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXH2[mRpUUN3ME2wMlMzOTFzIN88US=> NIfkUFlUSU6JRWK=
UACC-62 MoT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETVc4NKSzVyPUCuN|IzOjdizszN NH22W4VUSU6JRWK=
HuCCT1 NXnHSnJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7UbYFKSzVyPUCuN|IzQDNizszN M{XienNCVkeHUh?=
CTB-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHuyTXdKSzVyPUCuN|I4PTNizszN NUfWSmhPW0GQR1XS
NTERA-S-cl-D1 M3PCd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwM{K4N|Yh|ryP NHz3PIhUSU6JRWK=
T-24 M{Kz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwM{OxOVkh|ryP NHPTOINUSU6JRWK=
KYSE-70 NXTvWJI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PQW2lEPTB;MD6zN|I5OyEQvF2= NV\DRVhoW0GQR1XS
SW626 NHGzXnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVqwb45oUUN3ME2wMlM{PTN{IN88US=> NV60T3hzW0GQR1XS
LB996-RCC MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XkTGlEPTB;MD6zN|YyQSEQvF2= NXLPPHJrW0GQR1XS
DMS-273 NUTWW3FHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPkWGJKSzVyPUCuN|M6OTZizszN NELwVVVUSU6JRWK=
SW1783 NY\nTGVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPWZmpKSzVyPUCuN|M6QTdizszN NYHVRppyW0GQR1XS
KU812 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXJTnVKSzVyPUCuN|QxOzhizszN MnfuV2FPT0WU
HSC-2 Mnm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXj2Upp[UUN3ME2wMlM1ODV|IN88US=> M2\JW3NCVkeHUh?=
A3-KAW MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHXTWM2OD1yLkO0NVYzKM7:TR?= MXLTRW5ITVJ?
COLO-684 MoLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPCR4RKSzVyPUCuN|Q2ODFizszN M2rYdHNCVkeHUh?=
NCI-H2405 NInUfWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDnTXNKSzVyPUCuN|Q3OzFizszN NUL3O|BEW0GQR1XS
NCI-H2228 NFPjUm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwM{WzOVch|ryP M3LtfnNCVkeHUh?=
NB13 NX7xZ4k1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DRSWlEPTB;MD6zOlgzQSEQvF2= M1HmR3NCVkeHUh?=
no-11 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2GxOGlEPTB;MD6zOlk2KM7:TR?= MXHTRW5ITVJ?
DK-MG M37TSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXMSpNVUUN3ME2wMlM4OTh6IN88US=> Mn7kV2FPT0WU
NBsusSR MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjqfZZKSzVyPUCuN|czQDVizszN MYLTRW5ITVJ?
KP-N-YS NHXobplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1G4cWlEPTB;MD6zO|Q3OyEQvF2= NXrv[YJYW0GQR1XS
CFPAC-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmm4TWM2OD1yLkO3OVE5KM7:TR?= Mn;hV2FPT0WU
KARPAS-45 MkPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\pVXRKSzVyPUCuN|c5PjJizszN NFjlcVNUSU6JRWK=
NCI-H1793 NGPjc3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGW5eoRKSzVyPUCuN|g2OSEQvF2= NHPFSlVUSU6JRWK=
HCE-T MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTxTJpuUUN3ME2wMlM5PjB|IN88US=> MUfTRW5ITVJ?
NCI-H520 MmraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwM{i3NFMh|ryP NYnoZYdsW0GQR1XS
HCC2157 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHS0eJRKSzVyPUCuN|g4QDFizszN MXnTRW5ITVJ?
EW-18 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{P5WWlEPTB;MD6zPFk1OSEQvF2= NXXTXXdGW0GQR1XS
RO82-W-1 Mn3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVT5[GhXUUN3ME2wMlM6Pjl7IN88US=> M4rVZXNCVkeHUh?=
HuP-T3 NFLLVGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnQUnVKSzVyPUCuOFAyPDNizszN NWHIUYZoW0GQR1XS
PANC-10-05 NWP4d2Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH32e5lKSzVyPUCuOFEyPyEQvF2= MoHnV2FPT0WU
NCI-H1703 M1;VUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PyXmlEPTB;MD60NVQ1PiEQvF2= MXTTRW5ITVJ?
TE-10 NUj5fmFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwNEG0OFch|ryP NVLVN|BUW0GQR1XS
HOS NWftZVdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mon0TWM2OD1yLkSxOlgzKM7:TR?= NFzUe2xUSU6JRWK=
LN-405 NI\QTIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3FN4ZKSzVyPUCuOFE3QDdizszN Ml70V2FPT0WU
A427 NILUcYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nQXmlEPTB;MD60NVk5OSEQvF2= Mn3nV2FPT0WU
CAL-12T MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjEOIJKSzVyPUCuOFI4QCEQvF2= Mm\RV2FPT0WU
SW756 NFrROnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFz1NHlKSzVyPUCuOFQyQDNizszN MWfTRW5ITVJ?
YAPC MlyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHzTWM2OD1yLkS1NFgh|ryP NYX0XnA5W0GQR1XS
GOTO MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPXXJd7UUN3ME2wMlQ2OTZizszN M1KxW3NCVkeHUh?=
C3A MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFG1Z3BKSzVyPUCuOFU1OzdizszN NVr3SHplW0GQR1XS
UM-UC-3 NVjtZYVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonNTWM2OD1yLkS1OFch|ryP NXLoW3pQW0GQR1XS
NCI-H1573 NULXbWFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\oTWM2OD1yLkS1OVY6KM7:TR?= MXLTRW5ITVJ?
LS-411N M2fZT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwNE[1Nlch|ryP NY\nTGwzW0GQR1XS
COR-L23 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELQWmFKSzVyPUCuOFY4PjRizszN MnPWV2FPT0WU
HCE-4 MmPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjaTGtKSzVyPUCuOFc1PDZizszN M3jp[HNCVkeHUh?=
NCI-H2291 Mmn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3jbFRKSzVyPUCuOFc5QTZizszN M2\De3NCVkeHUh?=
A101D MmmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTBwNEiwOVMh|ryP M33WWHNCVkeHUh?=
HT-3 M4q5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnxVXpbUUN3ME2wMlQ5OjF5IN88US=> NVHaXmRTW0GQR1XS
HOP-62 M4fz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInxfZVKSzVyPUCuOFk5PjVizszN NVvxVIZSW0GQR1XS
PC-3 M33WVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTBwNUG1NFch|ryP NFzBPWhUSU6JRWK=
CTV-1 M4jJS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYSwVJRqUUN3ME2wMlUzPjZ7IN88US=> MoDEV2FPT0WU
PANC-08-13 NEnwSlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPUdm9KSzVyPUCuOVMyPzdizszN M4OwPHNCVkeHUh?=
CAL-120 M1X0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nTc2lEPTB;MD61N|M6QSEQvF2= MorZV2FPT0WU
UMC-11 Mk\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4S1eWlEPTB;MD61OVI{PCEQvF2= NVzTRVFCW0GQR1XS
MSTO-211H NIXYeXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTBwNUW3OlIh|ryP NUm3OYJjW0GQR1XS
NCI-H2126 NVTVeFRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTBwNU[4NVUh|ryP M3jB[nNCVkeHUh?=
SNU-C2B NULXZmlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\BTWM2OD1yLkW3PVc4KM7:TR?= NGTCZo9USU6JRWK=
DBTRG-05MG M1:4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVH5NoZuUUN3ME2wMlU5ODV|IN88US=> Mlz4V2FPT0WU
MKN1 NGewZ5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYKyd3FwUUN3ME2wMlU5Pzh|IN88US=> NWP3cHpJW0GQR1XS
ES3 M3nxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDoTWM2OD1yLkW5NVI1KM7:TR?= MV3TRW5ITVJ?
OVCAR-3 MkfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlj1TWM2OD1yLkW5N|QyKM7:TR?= MWjTRW5ITVJ?
ACHN M{DS[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7M[WtKSzVyPUCuOlA2PjlizszN NWjR[4NKW0GQR1XS
SW872 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTBwNkC3OlMh|ryP MXrTRW5ITVJ?
CP66-MEL NG[1TG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTsTWM2OD1yLk[wPVY6KM7:TR?= MYfTRW5ITVJ?
NCI-H661 M2HWWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\4fXRKSzVyPUCuOlEyODRizszN MVfTRW5ITVJ?
UACC-893 MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHS5dlFKSzVyPUCuOlM3QDFizszN MlfKV2FPT0WU
JVM-3 NUnJU2pHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfvb3B6UUN3ME2wMlY{QDB2IN88US=> M4DN[XNCVkeHUh?=
SF268 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmG1TWM2OD1yLk[0N|Q6KM7:TR?= NYfnbVM4W0GQR1XS
OCI-AML2 MmHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHrTWM2OD1yLk[1N|k4KM7:TR?= MoLiV2FPT0WU
RPMI-8226 NYC5WVE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn6yTWM2OD1yLk[2N|I{KM7:TR?= NYnWdIM3W0GQR1XS
MKN28 M4H1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV6wXVJ3UUN3ME2wMlY3PjJ2IN88US=> NGH2bYRUSU6JRWK=
MDA-MB-453 NH7kSmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PFemlEPTB;MD62O|E5KM7:TR?= NXzLe4g{W0GQR1XS
BV-173 NVmwRWNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfIT|BvUUN3ME2wMlY5Pjd7IN88US=> NVnJXotPW0GQR1XS
NCI-H358 M1nvXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojRTWM2OD1yLk[4O|I3KM7:TR?= NIXhcGhUSU6JRWK=
NCI-H1651 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2j2NWlEPTB;MD63JO69VQ>? MYPTRW5ITVJ?
MDA-MB-415 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF65[HhKSzVyPUCuO|A5OjlizszN MoDWV2FPT0WU
8305C NUjvWZQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPuTWM2OD1yLkeyOFk5KM7:TR?= NYHRZ|ltW0GQR1XS
EFM-19 NWPTTXRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rH[WlEPTB;MD63N|Y4OSEQvF2= NUPTeIxDW0GQR1XS
RERF-LC-MS MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTTRpFKSzVyPUCuO|Q3OTNizszN MXPTRW5ITVJ?
A388 NHu0fWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrDSFJKSzVyPUCuO|Y1PjdizszN MV\TRW5ITVJ?
GI-ME-N MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTBwN{eyN|Uh|ryP NWLX[WJ7W0GQR1XS
IGR-1 NFzxelRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjqT3dKSzVyPUCuO|kxPDNizszN MmXrV2FPT0WU
LNCaP-Clone-FGC NFG1RmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4L4c2lEPTB;MD64NFAxPCEQvF2= M{\1ZXNCVkeHUh?=
SK-MEL-3 MnTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInERXBKSzVyPUCuPFE2ODhizszN M4[5d3NCVkeHUh?=
UACC-257 M{TiXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTsPXBKSzVyPUCuPFIzOzFizszN MV7TRW5ITVJ?
OE33 NF7ueFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHOTWM2OD1yLki1NVAyKM7:TR?= MXvTRW5ITVJ?
QIMR-WIL MnfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwOEWxOFEh|ryP NFTCTXVUSU6JRWK=
NCI-H2009 NULGZVZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDmeGlKSzVyPUCuPFU{OTFizszN MUHTRW5ITVJ?
NCI-H522 NWLD[4VST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4X6VWlEPTB;MD64O|c5OyEQvF2= NULqXWc2W0GQR1XS
Saos-2 M13qNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTQTWM2OD1yLki3PFcyKM7:TR?= NV;XZVFOW0GQR1XS
NB17 NF3IW3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGm5dmZKSzVyPUCuPFgxOjVizszN M2XPXXNCVkeHUh?=
D-392MG NXqwcHVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjvXoFKSzVyPUCuPFk{PTZizszN MoOxV2FPT0WU
SHP-77 M2PuXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PiRWlEPTB;MD65NFQ5PSEQvF2= M3HabnNCVkeHUh?=
SK-MEL-30 Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEX5S45KSzVyPUCuPVEyQDVizszN NUX2[GZEW0GQR1XS
GCIY M2H1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwOUG4OFMh|ryP MYnTRW5ITVJ?
HCC70 NILt[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwOUKwOVkh|ryP M1jkNnNCVkeHUh?=
LU-65 MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13Mb2lEPTB;MD65NlU6OSEQvF2= NGnaN|ZUSU6JRWK=
NCI-H1563 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTBwOUS4OlUh|ryP NXjTZZl6W0GQR1XS
KURAMOCHI M4LCWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{[0RWlEPTB;MD65OVE6OiEQvF2= NUm5O4NPW0GQR1XS
PA-1 NHfH[W1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzSeW92UUN3ME2wMlk2PDJ2IN88US=> MV;TRW5ITVJ?
NOS-1 NXzIfoVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTBwOUe0PFkh|ryP MlvsV2FPT0WU
NCI-H69 MnHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7sfINKSzVyPUCuPVc3OzRizszN M{PNWXNCVkeHUh?=
KYSE-450 NEXkdIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;JTWM2OD1yLkm4OlI3KM7:TR?= MkHvV2FPT0WU
8505C NYrmR4FtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfXdIJoUUN3ME2wMlk6QTh{IN88US=> M3frNXNCVkeHUh?=
TGBC24TKB NIn5WoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXO[3E1UUN3ME2xMlAxODh2IN88US=> MlTQV2FPT0WU
PFSK-1 NFG2enVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn4N5N[UUN3ME2xMlAyPDJ6IN88US=> MnjmV2FPT0WU
EKVX M{jIPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfQNGZKSzVyPUGuNFMyOjFizszN M4S1NXNCVkeHUh?=
RCM-1 M{TzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\VZmlEPTB;MT6wOVUxPyEQvF2= NV;1XFVHW0GQR1XS
SW900 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\1TWM2OD1zLkC3PFMh|ryP NU\pXJBYW0GQR1XS
D-542MG M2G0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;SUmlEPTB;MT6wO|g2PSEQvF2= NIfRfZFUSU6JRWK=
SK-PN-DW M4\xXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfGNHNKSzVyPUGuNVAxPTZizszN NFLVT4xUSU6JRWK=
NCI-H727 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnDOY5KSzVyPUGuNVAyPTRizszN NW\6WGNQW0GQR1XS
SW837 NFq3SoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3CSZNKSzVyPUGuNVA6PTRizszN MmrtV2FPT0WU
BT-20 M{Pvdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTFwMUGyNFQh|ryP MnvWV2FPT0WU
RH-18 MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{T5SWlEPTB;MT6xN|ExOyEQvF2= MnvsV2FPT0WU
TE-12 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HLS2lEPTB;MT6xN|M{OyEQvF2= MkHRV2FPT0WU
NB10 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M122fGlEPTB;MT6xN|M1PCEQvF2= MnLVV2FPT0WU
AU565 Mm\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFK2PG1KSzVyPUGuNVU6PzNizszN MkW4V2FPT0WU
OAW-42 NHvjfohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHTb|JKSzVyPUGuNVg{ODZizszN M1j4ZnNCVkeHUh?=
DJM-1 NFm0PYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTFwMUm4PFEh|ryP MoS5V2FPT0WU
HH NFHVWGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvnTWM2OD1zLkKzPFMyKM7:TR?= MorpV2FPT0WU
LAMA-84 NXP3RZZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjXfGhKSzVyPUGuNlc{QTRizszN MnuzV2FPT0WU
KNS-42 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTTTWM2OD1zLkOwNlk3KM7:TR?= MmLqV2FPT0WU
NCI-H2052 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPTb4o3UUN3ME2xMlMxPTB5IN88US=> M4q0eHNCVkeHUh?=
MLMA M1m4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTFwM{K0NFch|ryP MlXoV2FPT0WU
NB12 NYXCRWZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3TTWM2OD1zLkO1OlM3KM7:TR?= NV;ZWm9CW0GQR1XS
NCI-H1838 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXZTWM2OD1zLkO2N|A3KM7:TR?= NH;XOGJUSU6JRWK=
NCI-H526 MnfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PxVGlEPTB;MT6zO|g2OyEQvF2= NXzycY5mW0GQR1XS
LS-123 M13C[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV2xeYJGUUN3ME2xMlM6ODl2IN88US=> NHKycpNUSU6JRWK=
HDLM-2 NH7Bcm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlX4TWM2OD1zLkO5NlcyKM7:TR?= M1P0R3NCVkeHUh?=
MC-IXC MnXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jZRWlEPTB;MT60NlM4OSEQvF2= Ml\KV2FPT0WU
HCT-15 MlnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELVb4VKSzVyPUGuOFMxPjhizszN M1vhfnNCVkeHUh?=
NCI-H596 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LoVWlEPTB;MT60OVA3OSEQvF2= M1XZRXNCVkeHUh?=
ZR-75-30 NXW2WoxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnmb5ZKSzVyPUGuOFcxQDJizszN MYTTRW5ITVJ?
A704 M{\o[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkixTWM2OD1zLk[2OVY{KM7:TR?= Ml3iV2FPT0WU
OVCAR-4 MlfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTFwNkm2NFch|ryP NXjhXHljW0GQR1XS
SW1417 M1vtfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MomyTWM2OD1zLkeyPFQ6KM7:TR?= Mo\FV2FPT0WU
CAS-1 NWK0W2czT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTFwN{O5N|Yh|ryP NUfSbnB5W0GQR1XS
IST-SL1 NVzRWpBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvZfXBKSzVyPUGuO|k4PTlizszN MYPTRW5ITVJ?
A253 NH3t[3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvjbYxqUUN3ME2xMlgzOjN7IN88US=> M2H6fHNCVkeHUh?=
EW-16 MontS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LoOmlEPTB;MT64Nlg4PSEQvF2= MWXTRW5ITVJ?
SK-NEP-1 M1Pkemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjsUYZKSzVyPUGuPFY6QDhizszN MUXTRW5ITVJ?
NCI-H226 NI[5eINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfHWWQ1UUN3ME2xMlg6OzV7IN88US=> NVL4W2RQW0GQR1XS
HOP-92 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYO1UGNWUUN3ME2xMlk3ODl7IN88US=> MoXhV2FPT0WU
NCI-H441 MkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTJwMEKzN|ch|ryP MonkV2FPT0WU
LU-139 NHrRfWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTJwMEOxNVQh|ryP NGXzXnNUSU6JRWK=
SJRH30 M37IN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mor3TWM2OD1{LkC0NlU{KM7:TR?= NXPRU2lLW0GQR1XS
MG-63 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LMXWlEPTB;Mj6xOFEyOSEQvF2= NHzDNmFUSU6JRWK=
NH-12 MoHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zPUmlEPTB;Mj6xOVAxPiEQvF2= MkHFV2FPT0WU
NB7 M1;COmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoD1TWM2OD1{LkG5Olc{KM7:TR?= MliwV2FPT0WU
LB771-HNC M17lcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTJwMkC1PVUh|ryP MYjTRW5ITVJ?
HCC1569 NEHHc5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3joN2lEPTB;Mj6yOFU5OyEQvF2= NGflZ5hUSU6JRWK=
D-283MED NXO5eIJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJwMkS3PFIh|ryP MV\TRW5ITVJ?
J-RT3-T3-5 NWTIVJVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTJwMkWzOVEh|ryP NH7TdJNUSU6JRWK=
ATN-1 NYn5[WdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlq5TWM2OD1{LkOzNFgzKM7:TR?= NUHob4h[W0GQR1XS
HCC1954 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HFWWlEPTB;Mj6zOFQxQCEQvF2= NHzSS2ZUSU6JRWK=
SCC-15 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nie2lEPTB;Mj6zPVMyOiEQvF2= M3zHNnNCVkeHUh?=
COLO-668 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PLWGlEPTB;Mj60N|Ih|ryP MlLEV2FPT0WU
LB373-MEL-D NHrOWGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTJwNUS2O|ch|ryP MYnTRW5ITVJ?
no-10 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUX1T2Z3UUN3ME2yMlU1QTR5IN88US=> MWjTRW5ITVJ?
HT-1197 NUX5UGF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTJwNkOxPFgh|ryP NFrGWJFUSU6JRWK=
DU-145 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fUVGlEPTB;Mj63PVE3OiEQvF2= MlnIV2FPT0WU
SK-N-AS NGS5cmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDSOXhvUUN3ME2yMlg1Pjl{IN88US=> M2LWVnNCVkeHUh?=
MOLT-4 NI\UblFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TjR2lEPTB;Mj64OVMzOiEQvF2= MYPTRW5ITVJ?
EW-22 NGj0dJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTJwOUK4OFEh|ryP M3HHO3NCVkeHUh?=
DB NYGxdZpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHrTWM2OD1{Lkm3O|U6KM7:TR?= MXTTRW5ITVJ?
HL-60 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTNwMESzO|Yh|ryP M1noTnNCVkeHUh?=
SK-N-DZ NXjWb3o4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDPTWM2OD1|LkC1NFc2KM7:TR?= MoW0V2FPT0WU
NY M4XZPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrKNpRKSzVyPUOuNFg2PDJizszN M2XjenNCVkeHUh?=
T47D MmHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmT2TWM2OD1|LkGwOVU5KM7:TR?= NXvWc2hQW0GQR1XS
NCI-H2029 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3KyXWlEPTB;Mz6yNlQ4PyEQvF2= NX7sU5ZMW0GQR1XS
KARPAS-299 MnPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nOSGlEPTB;Mz6yOlAzPyEQvF2= M1nzNnNCVkeHUh?=
KM-H2 MlS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPZTWM2OD1|LkOwOlgh|ryP NYnwSm53W0GQR1XS
CHP-134 MoXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnQTWM2OD1|LkS3N|kh|ryP M3rFdXNCVkeHUh?=
22RV1 NWnn[45WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljaTWM2OD1|LkS5NVY5KM7:TR?= MmThV2FPT0WU
NB5 NVzkeJhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[1NpBKSzVyPUOuOVA3QDlizszN NXTSWZlsW0GQR1XS
CW-2 MkPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3Y[|hKSzVyPUOuOVU{OTRizszN MWfTRW5ITVJ?
EFO-21 NXPp[GJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nzZmlEPTB;Mz61Olk1KM7:TR?= MlG3V2FPT0WU
HuH-7 Mlq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkm2TWM2OD1|LkW4OFE1KM7:TR?= MmDwV2FPT0WU
ALL-PO M1[3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTNwNkKzN|Uh|ryP M336T3NCVkeHUh?=
EM-2 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPHWHh3UUN3ME2zMlY6ODFzIN88US=> MXnTRW5ITVJ?
KLE MmP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVntcIlmUUN3ME2zMlc{ODJ7IN88US=> MUXTRW5ITVJ?
NEC8 NXLBdZAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfQO2hKSzVyPUOuPVE5ODhizszN NXLtVVRrW0GQR1XS
KP-N-YN NGXPcZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTNwOUO0O|Yh|ryP NWLzUWhnW0GQR1XS
SK-MEL-1 NUHKWoh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX72W4dZUUN3ME20MlA{PTF6IN88US=> MmPSV2FPT0WU
CAL-54 MoHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrXUmdEUUN3ME20MlA2QTFizszN MV\TRW5ITVJ?
MS-1 NX2ySZRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;Uc3NbUUN3ME20MlE3OTV3IN88US=> MWrTRW5ITVJ?
NCI-H209 M13ScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NES1N4hKSzVyPUSuNlk6QTlizszN M2C2eHNCVkeHUh?=
NOMO-1 M1fpTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jKbGlEPTB;ND6zNlE{OSEQvF2= M4DtcXNCVkeHUh?=
RPMI-2650 NGTtdYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTRwM{[zNlch|ryP NXS3O5IyW0GQR1XS
NCI-H810 NVvEeJRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\idYhKSzVyPUSuN|k4OzZizszN NUe3W5lVW0GQR1XS
Ca9-22 NVzmSY1FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTRwNEW2PVEh|ryP MnnOV2FPT0WU
ES4 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLHT3JKSzVyPUSuOFcxQTVizszN M4nPe3NCVkeHUh?=
ES6 NUS1OXN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;hO|dKSzVyPUSuOFk3PTdizszN MoPxV2FPT0WU
DMS-114 NVvBTYpGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTRwNUS2PVEh|ryP MlznV2FPT0WU
ONS-76 MmDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTRwNUe5OUDPxE1? MVnTRW5ITVJ?
K-562 MkLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDzU3pRUUN3ME20Mlc{QDF2IN88US=> NGDQblFUSU6JRWK=
MHH-NB-11 NGS3OmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTUfoZ3UUN3ME20Mlc2PDZzIN88US=> Mn\wV2FPT0WU
Calu-3 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7pRlNKSzVyPUSuO|g2PDhizszN MX7TRW5ITVJ?
HT55 NWS1[VN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUj2TIxQUUN3ME20Mlg1PTR3IN88US=> M{T0Z3NCVkeHUh?=
SK-N-FI MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPUU4tKSzVyPUSuPFUxODlizszN MWXTRW5ITVJ?
ES1 M2nmPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvoTWM2OD12Lki2NFU4KM7:TR?= M4fT[HNCVkeHUh?=
SF126 NGnQSYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorsTWM2OD12LkmzNVg1KM7:TR?= NYLEPVFvW0GQR1XS
ES5 MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3i1e2lEPTB;NT6xNlQzPyEQvF2= MoWzV2FPT0WU
LoVo M1z4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUCydlRIUUN3ME21MlE2QDdzIN88US=> NXfSfnBNW0GQR1XS
SNU-387 NGXGcIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;IdYVKSzVyPUWuN|I{OzlizszN NInxXllUSU6JRWK=
C8166 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PxPGlEPTB;NT6zOlM{QSEQvF2= M3HITHNCVkeHUh?=
LS-1034 NVS3[pFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzmc|hKSzVyPUWuOFI{ODdizszN M3W5PXNCVkeHUh?=
GR-ST NWnDWmptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHKWVFKSzVyPUWuOVIzODFizszN M1\xW3NCVkeHUh?=
NCI-H1092 NFvnZZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTVwN{K4OFMh|ryP Mn3SV2FPT0WU
647-V NFPEe5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrvTWM2OD13Lke0O|A3KM7:TR?= MW\TRW5ITVJ?
EW-13 NEntdWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\vO2NRUUN3ME21Mlc3PjJ5IN88US=> M2fJXXNCVkeHUh?=
KGN MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYroUnJvUUN3ME22MlA6QTJzIN88US=> M1;JbnNCVkeHUh?=
D-423MG NHL0[YtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHXPYFKSzVyPU[uOFAzQDRizszN MkjDV2FPT0WU
ECC10 NGDwc5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUe5XmY2UUN3ME23MlExOTBzIN88US=> NFPxU2tUSU6JRWK=
TE-5 NFTKN|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXi1[npIUUN3ME23MlQyOjl6IN88US=> M4L1c3NCVkeHUh?=
P12-ICHIKAWA MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLoXZFKSzVyPUeuOFU2OjNizszN NHv1fYZUSU6JRWK=
NCI-H82 M4LIbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXOUlg5UUN3ME23MlQ2PzBzIN88US=> MVTTRW5ITVJ?
NCI-H1993 NFvLNJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTdwOEOwOlMh|ryP M3HlbHNCVkeHUh?=
RH-1 NGjSemdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HFU2lEPTB;Nz64OVI1PCEQvF2= MXTTRW5ITVJ?
SW948 NF7sR3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DXO2lEPTB;Nz65OlA1QSEQvF2= MX7TRW5ITVJ?
CAL-33 NUnZVVFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jINWlEPTB;Nz65PVk{QCEQvF2= MlvYV2FPT0WU
U-266 MmfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTneFBKSzVyPUiuNVU4PzdizszN M4racnNCVkeHUh?=
CAL-72 NFi2d|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXHTWM2OD16LkKwN|Ih|ryP NGfOZ3NUSU6JRWK=
SNU-423 M{PNUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfiT3dkUUN3ME25MlM3PjZ4IN88US=> NUHIW3FJW0GQR1XS
KG-1 NVfkVYxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jIeWlEPTB;OT61PFQ2PiEQvF2= MkDYV2FPT0WU
HCC1395 M3jkfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLPbllQUUN3ME25MlkzOzV{IN88US=> NX2xSXFyW0GQR1XS
BE-13 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvrTWM2OD1zMD64PFkzKM7:TR?= NWHxR|FxW0GQR1XS
MKN7 NGHRWndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3STZNpUUN3ME2xNE46PzZ3IN88US=> M1\uSXNCVkeHUh?=
697 M1Tp[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7rTWM2OD1zMT6xOFczKM7:TR?= MnWyV2FPT0WU
LU-135 M1TY[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTFzLkKzNFch|ryP MofzV2FPT0WU
ES7 MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfjVJB6UUN3ME2xNU4{OzF|IN88US=> MmLvV2FPT0WU
SK-HEP-1 M4j2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPGU2xKSzVyPUGxMlc3PDZizszN M2\yUHNCVkeHUh?=
BEN MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPTSnRKSzVyPUGxMlg2OSEQvF2= M{DkOXNCVkeHUh?=
NCI-H1770 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LIb2lEPTB;MUKuNVI3KM7:TR?= M4Hwc3NCVkeHUh?=
SW13 M4LFNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TZNmlEPTB;MUKuNVU1OSEQvF2= MkX2V2FPT0WU
MZ1-PC MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlH5TWM2OD1zMj61OFUzKM7:TR?= MmGwV2FPT0WU
Mo-T NGnWVZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TkNmlEPTB;MUKuO|QzOSEQvF2= M3SydnNCVkeHUh?=
HLE M1L3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTF{LkiyNVUh|ryP Mmj3V2FPT0WU
RCC10RGB NILIeG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3vZ3NKSzVyPUGzMlY4OSEQvF2= NXG1N2lUW0GQR1XS
COLO-320-HSR NHyzPGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTF|LkezPFEh|ryP NYrxdWV[W0GQR1XS
BHT-101 NVfuS4hXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTF|LkizOFUh|ryP M{DvPXNCVkeHUh?=
OCUB-M M4K4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTF2LkG2NFIh|ryP NU\CXmt{W0GQR1XS
MEG-01 M3;hd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4C3WWlEPTB;MUSuN|cxQCEQvF2= NFW0cJBUSU6JRWK=
RS4-11 M33a[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoOwTWM2OD1zND63OFIh|ryP MUfTRW5ITVJ?
MN-60 M{PJXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mny2TWM2OD1zND63PFk1KM7:TR?= NYHVUphRW0GQR1XS
NCI-H1304 Mmq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlH4TWM2OD1zNT6wOFI2KM7:TR?= NX[5cVlTW0GQR1XS
Ramos-2G6-4C10 NULEbodTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17aOGlEPTB;MUWuNFU5OSEQvF2= NIHUR3VUSU6JRWK=
NCI-H2342 M3zaRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTF3LkKwOFQh|ryP NIXFVVRUSU6JRWK=
LAN-6 M1T4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTF3LkS0NVQh|ryP Mle0V2FPT0WU
JVM-2 Mni1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fPZWlEPTB;MUWuOVc1QCEQvF2= NYD2Z3pmW0GQR1XS
P30-OHK M3G3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\lTWM2OD1zNj6wOlE1KM7:TR?= M{HWenNCVkeHUh?=
C-33-A Mo\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGK2XJZKSzVyPUG2MlYzOTRizszN MnTRV2FPT0WU
RPMI-8866 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rpcGlEPTB;MU[uPFQ6PiEQvF2= MV3TRW5ITVJ?
NCI-H630 NWG5O|FLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnL3TWM2OD1zNj64OVM4KM7:TR?= MmDEV2FPT0WU
KYSE-140 NF\hTmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTF5LkKwNlgh|ryP M4PobnNCVkeHUh?=
T84 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jxOWlEPTB;MUiuPFY6PSEQvF2= M2XQO3NCVkeHUh?=
KU-19-19 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M334WWlEPTB;MUiuPVYxQCEQvF2= NV[5T4FxW0GQR1XS
BALL-1 NFHsZ4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3[xUGlEPTB;MUmuN|M6QSEQvF2= Mm\NV2FPT0WU
Calu-6 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWK5SI5CUUN3ME2xPU41QTJizszN Mlj4V2FPT0WU
EGI-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTF7LkW5PEDPxE1? NGLoWZJUSU6JRWK=
MFH-ino MkTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[5TWM2OD1zOT63OFU1KM7:TR?= MnGwV2FPT0WU
GB-1 M4DVemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnyZolsUUN3ME2yNE4{PTN3IN88US=> M3LCdnNCVkeHUh?=
NCI-H1693 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF65O49KSzVyPUKwMlY2ODVizszN NGLCT2dUSU6JRWK=
SW1116 MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4r0N2lEPTB;MkCuPVM3OiEQvF2= MnXHV2FPT0WU
H-EMC-SS MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjJUJVCUUN3ME2yNk4xPDVizszN MmfzV2FPT0WU
D-502MG NYjaS2k4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4exW2lEPTB;MkKuPFI3OSEQvF2= NVzUVVFIW0GQR1XS
IA-LM NFLKfVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nISmlEPTB;MkOuNlQ6OyEQvF2= M2HVZ3NCVkeHUh?=
SW1463 NGrCfVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fnN2lEPTB;MkOuO|kh|ryP NGfsNYFUSU6JRWK=
JAR NWKyZmxtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2CyOmlEPTB;MkSuN|I6OyEQvF2= MYfTRW5ITVJ?
HT NGLSVpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfETWM2OD1{ND60O|U{KM7:TR?= NWna[W1NW0GQR1XS
LCLC-103H NHj4OVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGqyW5ZKSzVyPUK0Mlg1PDlizszN MVLTRW5ITVJ?
SNU-449 M4Wxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jGSmlEPTB;MkSuPFc1OSEQvF2= NY\0ZY9vW0GQR1XS
KE-37 MmroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrndVVKSzVyPUK1MlA6OjhizszN MV7TRW5ITVJ?
NCI-H1623 Mn;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7B[VNrUUN3ME2yO{4yOzB|IN88US=> Ml;yV2FPT0WU
MOLT-13 NY\4fldoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTJ5LkO1NVYh|ryP NUG1TmxWW0GQR1XS
COLO-741 MlL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzj[mtKSzVyPUOxMlM{OzNizszN NWDjWlFuW0GQR1XS
NB6 MmjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkToTWM2OD1|Mj6yPFc3KM7:TR?= NXP0W29OW0GQR1XS
MOLT-16 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHiVFhKSzVyPUOzMlAxPTVizszN M4HpTHNCVkeHUh?=
IST-MES1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXmNVd1UUN3ME2zOE4xPTRzIN88US=> NELER2NUSU6JRWK=
A4-Fuk M2Xm[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fOV2lEPTB;M{WuNFY3KM7:TR?= NHLGXWdUSU6JRWK=
CAL-85-1 NVrQVXl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWK5cJdjUUN3ME2zOU4zQDF5IN88US=> MmTYV2FPT0WU
CCRF-CEM NYr5S49qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfCUFBKSzVyPUO3MlE2OzZizszN NILvS4dUSU6JRWK=
HAL-01 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTN6LkS4PFkh|ryP MnnpV2FPT0WU
HEL Mn;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2X4dWlEPTB;NEOuN|QxQSEQvF2= M4TZZXNCVkeHUh?=
EW-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTR|LkS3Olgh|ryP MWrTRW5ITVJ?
MDA-MB-231 NFzDTVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTR3LkGxPVkh|ryP NUnTUJZVW0GQR1XS
ABC-1 NHXGNoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIm5bZdKSzVyPUS2Mlg2OzhizszN Mn\rV2FPT0WU
NCI-H446 NEDx[IVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmOyTWM2OD12OD61NFU5KM7:TR?= M{\jNXNCVkeHUh?=
MHH-PREB-1 NFzWTVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmT4TWM2OD12OT62NFA4KM7:TR?= NFLOVHNUSU6JRWK=
DOHH-2 M1rTSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17ZTGlEPTB;NEmuOlY2PiEQvF2= MYrTRW5ITVJ?
GCT MkXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTR7Lk[5O|Yh|ryP M{XRWnNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo 17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. [1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. [2]

Protocol

Kinase Assay:[1]
+ Expand

Hsp90 binding assays:

Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl2, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
Cell Research:[1]
+ Expand
  • Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 5 days
  • Method: Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A490) of wells not containing cells is subtracted. Percentage of viable cells = (A490 of 17-AAG treated sample/A490 untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6
  • Formulation: Dissolved in DMSO, and diluted in egg phospholipids (EPL) vehicle
  • Dosages: ~50 mg/kg
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (170.73 mM)
Ethanol 5 mg/mL (8.53 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+corn oil
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 585.69
Formula

C31H43N3O8

CAS No. 75747-14-7
Storage powder
in solvent
Synonyms CP127374,NSC-330507, KOS 953

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00577889 Completed Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage IV Pancreatic Cancer National Cancer Institute (NCI) March 2008 Phase 2
NCT00546780 Completed Multiple Myeloma Bristol-Myers Squibb February 2008 Phase 3
NCT00093496 Completed Primary Peritoneal Cavity Cancer|Recurrent Ovarian Epithelial Cancer|Stage III Ovarian Epithelial Cancer|Stage IV Ovarian Epithelial Cancer National Cancer Institute (NCI) October 2007 Phase 2
NCT00514371 Completed Multiple Myeloma Bristol-Myers Squibb August 2007 Phase 2|Phase 3
NCT00779428 Completed Advanced Malignancies Bristol-Myers Squibb July 2006 Phase 2
NCT00354185 Terminated Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia National Cancer Institute (NCI) May 2006 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?

  • Answer:

    17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products

Tags: buy Tanespimycin (17-AAG) | Tanespimycin (17-AAG) supplier | purchase Tanespimycin (17-AAG) | Tanespimycin (17-AAG) cost | Tanespimycin (17-AAG) manufacturer | order Tanespimycin (17-AAG) | Tanespimycin (17-AAG) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID